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Abstract
Little is known about the mechanisms involved in the regulation of nociceptin and its receptor (nociceptin opioid peptide
receptor, NOP) in response to inflammation and pain in humans. In this study, specific signaling pathways contributing to the
regulation of nociceptin and NOP in human peripheral blood leukocytes were investigated. After approval by the ethics
committee, peripheral blood obtained from healthy donors was cultured with or without phorbol-12-myristate-13-acetate
(PMA). Prepronociceptin (ppNOC) and NOP mRNA were analyzed by real-time quantitative polymerase chain reaction, and
nociceptin concentrations in culture supernatants by fluorescent enzyme immunoassay. Nociceptin and NOP protein levels
in blood leukocyte subsets were determined using flow cytometry. To examine the contribution of signaling pathways to
ppNOC and NOP regulation, blood was pre-treated with kinase inhibitors specific for ERK, JNK, p38, and NFjB pathways
prior to culturing with or without PMA. PMA dose-dependently upregulated ppNOC mRNA but downregulated NOP
mRNA in human peripheral blood leukocytes. PMA 10 ng/ml increased ppNOC after 6 h and suppressed NOP after 3
h compared to controls (both P <0.005). Nociceptin concentrations were increased in supernatants of PMA-induced blood
samples after 24 h (P <0.005), whereas expression of cell-membrane NOP was decreased by PMA in blood leukocyte
subsets (all P <0.05). Blockade of ERK or p38 pathways partially prevented PMA effects on ppNOC and NOP mRNA (all P
<0.05). The combination of ERK and p38 inhibitors completely reversed the effects of PMA (P <0.05). ERK and p38 are two
major signaling pathways regulating nociceptin and its receptor in human peripheral blood leukocytes under inflammato-
ry conditions.
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Introduction
Opioids are powerful analgesics, but their widespread use
has been questioned of late due to their related side
effects, including respiratory depression, the risk of addic-
tion, and lack of evidence supporting long-term effective-
ness in the management of chronic pain.1,2 Thus,
alternative analgesics with a more favorable side effect
profile would be welcome treatment options.
Preclinical and clinical studies have indicated that
compounds targeting the nociceptin opioid peptide
receptor (NOP) are safe and effective alternatives to
opioids in the treatment of pain or inflammatory disor-
ders.3–5 Meanwhile, the role of NOP and its endogenous
ligand nociceptin in pain processing and inflammation
has been confirmed.3,6,7 Despite the close homology to
opioids and classical opioid receptors, NOP and noci-
ceptin are distinct from the opioid family.8–10 Classical
opioid receptors cannot be detected in human peripheral
blood cells, whereas both nociceptin and NOP are con-
stitutively expressed.11–13 NOP and nociceptin exert
immunomodulatory effects in circulating leukocytes
during nociceptive processes and inflammation.6,14
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Aberrant expression of NOP and nociceptin in periph-
eral blood of patients suffering from pain or inflamma-
tory diseases has been described previously.6,7,14,15
Analysis of mechanisms contributing to the regulation
of nociceptin and NOP may provide new insight into
the treatment of pain and inflammation. Previous exper-
imental approaches focused on signaling pathways
triggered by the activation of the nociceptin system or
the regulation of NOP and nociceptin mRNA expression
in astrocyte or MM6 cell cultures.16,17 In contrast, infor-
mation on signaling pathways involved in human blood
leukocytes is still scarce.
Ex vivo whole blood culture systems are suitable
models to investigate mechanisms of gene regulation in
different leukocyte subsets. Stimulation of blood cells
with phorbol-12-myristate-13-acetate (PMA) or lipo-
polysaccharide (LPS) is a common method used to acti-
vate leukocytes. Whereas LPS binds to a cell surface
receptor complex, PMA directly diffuses through the
cell membrane and activates protein kinase C in cyto-
plasm, triggering downstream intracellular signaling
pathways (ERK, JNK, p38, and NFjB).18,19 PMA has
frequently been used to stimulate cells by mimicking
human monocyte-to-macrophage differentiation and
has proven to be an optimal stimulus in immune
cells.20 In our previous studies, PMA was the only sub-
stance with an upregulating effect on nociceptin in com-
parison to other inflammatory stimuli.13,17
The aim of our study was to investigate signaling
pathways contributing to the regulation of NOP and
nociceptin mRNA expression in human blood leuko-
cytes under inflammatory conditions and to verify their
protein profiles in blood leukocyte subsets. The hypoth-
esis was that specific signal transduction pathways regu-
late nociceptin and its receptor in human peripheral
blood leukocytes.
Materials and methods
The study was approved by the local ethics committee
(Kantonale Ethikkommission: KEK 041/09). Fresh hep-
arinized blood samples were randomly obtained from
the Interregionale Blutspende SRK Bern directly before
the experiments. Experiments were not conducted in
parallel, but consecutively, and for each experiment,
blood of different donors was used. In the different
phases of the study, we did not have access to the
exact same number of volunteers available for blood
donation. In total, 50 donors were enrolled after giving
written informed consent. The eligibility criteria for
donation were age between 18 and 60 years, a body
weight of at least 50 kg, no medical or hospital treatment
received, no tattoo or piercing during the last four
months, and no major surgery or childbirth during the
last 12 months.
Whole blood cultures
Whole blood was cultured in 48-well flat-bottom culture
plates (BD Bioscience, Allschwil, Switzerland) at a
volume of 450ml per well. All reagents were freshly pre-
pared in RPMI 1640 medium supplemented with
100U/ml penicillin and 100mg/ml streptomycin (Sigma-
Aldrich, Buchs, Switzerland). Cultures were incubated at
37C in a 5% CO2 atmosphere.
Dose-response experiments. In a previous study, PMA
increased prepronociceptin (ppNOC) and decreased
NOP in MM6, with maximum effects after 24 h and
after 6 h, respectively.17 Therefore, ppNOC and NOP
mRNA were quantified in blood leukocytes after cultur-
ing with or without PMA (0.1–300 ng/ml; Sigma-
Aldrich, Buchs, Switzerland) for 24 h or 6 h. Blood sam-
ples from four donors were used in order to address
possible variation and to investigate dose-dependent
effects of PMA on ppNOC and NOP mRNA expression.
Based on these dose-response experiments, PMA
10 ng/ml was used in subsequent cultures. To investigate
the influence of PMA on nociceptin and NOP, whole
blood was treated with or without PMA 10 ng/ml for
0, 3, 6, 9, 12, 24, 48, and 72 h. In each experiment, sam-
ples without stimuli served as controls (control group).
Blood leukocytes were used for the detection of nocicep-
tin and NOP mRNA and protein levels. Culture super-
natants were collected for the measurement of nociceptin
concentrations.
Interference with signal transduction pathways. In order to
assess the involvement of ERK, JNK, p38, and NFjB
signaling pathways in the regulation of ppNOC and
NOP mRNA by PMA, intervention experiments
employing specific kinase inhibitors were conducted.
Blood was pre-treated with PD98059 (PD) 30 lM,
SP600125 (SP) 10 lM, SB203580 (SB) 10 lM, Bay
11-7871 (Bay) 3lM, or the combination of PD and SB
(all from Tocris Bioscience, Bristol, UK) for 1 h prior to
culturing with or without PMA 10 ng/ml for 6 and 24 h.
The concentrations of the inhibitors were based on doses
used in previous studies.17,21,22 A culture without any
stimulus and one cultured only with PMA 10 ng/ml
served as control group and reference group, respectively.
RNA isolation, cDNA synthesis, and relative
quantification
Samples were collected at the predefined time points, red
blood cells were lysed by the red blood cell lysis buffer,
and total RNA was isolated from the leukocytes using
the High Pure RNA Isolation Kit following the manu-
facturer’s protocol (Roche, Rotkreuz, Switzerland).
Leukocytes were resuspended in 200 ml PBS and lysed
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by 400 ml Lysis/Binding Buffer. Cell lysates were then
loaded into a High Pure Filter Tube and centrifuged.
DNase I solution was applied directly onto the glass
fiber fleece and incubated for 15 min at room tempera-
ture. Subsequently, the tube was washed with Wash
Buffer I and II, and RNA was eluted using 50 ml elution
buffer. RNA concentrations and purity were measured
by a NanoDrop 2000 (Thermo Scientific, Reinach,
Switzerland), and cDNA was subsequently synthesized
(Transcriptor First Strand cDNA Synthesis kit, Roche,
Rotkreuz, Switzerland).
Real-time quantitative polymerase chain reaction
(RT-qPCR) was performed using LightCyclerVR 480
Probes Master Mix and RealTime ready Assays on a
LightCyclerVR 480 II (Roche, Rotkreuz, Switzerland) as
published previously.17 Sequences of the primers used
for RT-qPCR are listed in Table 1. Hypoxanthine
phosphoribosyl-transferase 1 (HPRT1) and polymerase
(RNA) II (DNA directed) polypeptide A (POLR2A)
were selected as reference genes. cDNA from
SK-N-DZ, a human neuroblastoma cell line, served as
a calibrator. Standard curves of ppNOC, NOP, HPRT1,
and POLR2A were generated by PCR amplification in a
series of diluted cDNA in triplicate. Data of RT-qPCR,
including calibrator and samples, were analyzed using
the E-Method of the LightCyclerVR 480 Relative
Quantification Software. The calculation of the relative
amount of ppNOC, NOP, and the reference genes was
based on the crossing point value of a sample and the
efficiencies specified by the standard curves. After calcu-
lation of the target-to-reference ratios for each sample
and for the calibrator, the target/reference ratio of the
sample was then divided by the target/reference ratio of
the calibrator (normalized ratio).
Flow cytometry
Intracellular nociceptin and membrane NOP in blood
leukocyte subsets were detected by flow cytometry.
After 24 h of culturing with or without PMA 10 ng/ml,
blood was collected. Samples were incubated with
appropriate volumes of fluorochrome-conjugated mono-
clonal antibodies specific to granulocytes (FITC anti-
CD15, clone HI98), monocytes (PerCP/Cy5.5 anti-
CD14, clone HIB19), CD4þ T cells (Pacific Blue anti-
CD4, clone OKT4), CD8þ T cells (PE/Cy7 anti-CD8,
clone HIT8a), B cells (APC anti-CD19, clone HIB19),
and NK cells (APC/Cy7 anti-CD56, clone HCD56)
for 20 min at room temperature in the dark (reagents
from BioLegend, Koblenz, Germany). Blood was then
treated with BD FACS lysing solution for 15 min, cen-
trifuged (300 g, 5 min), and washed with staining buffer
(BD Biosciences, Allschwil, Switzerland). To block Fc
receptors, cells were suspended in 10% human AB
serum (Sigma-Aldrich, Buchs, Switzerland) for 10 min.
Subsequently, samples were added to the wells in a 96-
well U-bottom plate (TPP, Trasadingen, Switzerland)
and were incubated with anti-NOP antibody
(Neuromics, Edina, MN, USA)23 or an isotype control
antibody (Abcam, Cambridge, UK) with a final concen-
tration of 5 mg/ml for 1 h at room temperature. After
washing two times, cells were stained with PE-labelled
donkey anti-rabbit antibody at a final concentration of
1 mg/ml (BD Biosciences, Allschwil, Switzerland) for 1 h
in the dark at room temperature. Washed cells were
suspended in staining buffer, and measurements were
performed on a CytoFLEX within 6 h (Beckman
Coulter, Nyon, Switzerland). Details of intracellular
staining of nociceptin were published previously.17
Samples without PMA co-incubation served as controls.
To determine the autofluorescence of the cells, samples
with the same preparation for flow cytometry but with-
out any staining were used as negative controls.
Fluorescent enzyme immunoassay
Extracellular nociceptin protein levels in culture super-
natants were measured by fluorescent enzyme immuno-
assay (FEIA). After culturing with or without PMA 10
ng/ml for 0, 24, and 48 h, blood samples were collected
in the presence of the protease inhibitor aprotinin 600
KIU/ml (Phoenix Pharmaceuticals, Karlsruhe,
Germany) and centrifuged (16,000 g, 15min at 4C).
Supernatants were thoroughly mixed with an equal
amount of buffer A (Phoenix Pharmaceuticals,
Karlsruhe, Germany) and centrifuged at 12,000 g for
20 min. C-18 SEP cartridges were used to purify small
peptides from the supernatant solution, and nociceptin
Table 1. Real-time quantitative polymerase chain reaction primer sequences.
Gene Assay identification no.a Forward sequence Reverse sequence
ppNOC 118250 GGACAGCTTCGACCTGGAG TGACCTTGGTGCATGGAGT
NOP 126571 CCCAAGGAGGTTGCAGAA GCCGTAGATAACCTCCCAGA
HPRT1 102079 TGACCTTGATTTATTTTGCATACC CGAGCAAGACGTTCAGTCCT
POLR2A 102127 GCAAATTCACCAAGAGAGACG CACGTCGACAGGAACATCAG
Note: NOP: nociceptin opioid peptide receptor; ppNOC: prepronociceptin; HPRT1: hypoxanthine phosphoribosyl-transferase 1;
POLR2A: polymerase (RNA) II (DNA directed) polypeptide A.
aRealTime ready assay from Roche.
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protein levels were determined using the Nociceptin/
Orphanin FQ Fluorescent EIA kit (Phoenix
Pharmaceuticals, Karlsruhe, Germany) following the
manufacturer’s instructions.17
Statistical analysis
The primary endpoint was ppNOC and NOP mRNA
expression in blood leukocytes. For comparison of
ppNOC and NOP mRNA levels, whole blood was pre-
treated with or without specific kinase inhibitors prior to
PMA stimulation. Data are presented as medians with
interquartile ranges (IQR) or as box-and-whisker plots
showing medians, IQR, and 5 to 95 percentiles. The
Kruskal–Wallis test and the Wilcoxon signed-rank test
were applied for statistical comparisons. P <0.05 was
considered statistically significant. Results were cor-
rected for multiple testing.
Results
Dose-dependent effects of PMA
PMA dose-dependently upregulated ppNOC and downre-
gulated NOP mRNA expression in blood leukocytes after
24 and 6h, respectively (Figure 1). Based on these results,
PMA 10ng/ml was used in the subsequent experiments.
Time courses of ppNOC and NOP mRNA expression
Experiments addressing the time courses of ppNOC and
NOP mRNA expression in blood leukocytes cultured
with or without PMA 10 ng/ml are presented in
Figure 2. RT-qPCR analysis indicated that both
ppNOC and NOP mRNA are constitutively expressed
in human peripheral blood leukocytes (ppNOC: median
normalized ratio with IQR: 0.3 (0.2–0.5); NOP: 0.4 (0.3–
0.6)). ppNOC mRNA increased in a time-dependent
manner after exposure of the blood to PMA for up to
72 h. Elevated ppNOC mRNA levels were detected in
PMA-treated samples after 6 h compared to the control
group (1.1 (0.5–1.4) vs. 0.1 (0.0–0.4), P <0.005). In con-
trast, NOP mRNA was time-dependently suppressed by
PMA. A decrease in NOP mRNA was observed in the
PMA group after 3 h compared to baseline measures
(0.3 (0.1–0.3) vs. 0.5 (0.4–0.6), P <0.02).
PMA increased nociceptin concentrations in culture
supernatants
The FEIA revealed low nociceptin protein levels in the
supernatants at the start of the cultures (5.2 (4.7–6.8)
pg/ml). Nociceptin concentrations were increased in
supernatants of the PMA-induced blood after 24 h com-
pared to the controls (8.3 (4.7–15.9) vs. 5.0 (3.6–7.7) pg/
ml, P <0.005). In contrast, no difference was observed
between the two groups after 48 h (Figure 3).
Regulation of nociceptin and NOP proteins in
leukocyte subsets by PMA
To verify nociceptin and NOP protein profiles in different
blood leukocyte subsets, whole blood was cultured with or
without PMA 10 ng/ml for 24 h. Intracellular nociceptin
and membrane NOP were determined in six blood leuko-
cyte subtypes (granulocytes, monocytes, CD4þ T cells,
CD8þ T cells, B cells, and NK cells) identified by specific
cell surface markers. Representative gating strategy plots
Figure 1. PMA dose-dependent effects on ppNOC and NOP mRNA expression. Whole blood was cultured with different concen-
trations of PMA (0.1–300 ng/ml) or without PMA (control) for 24 h (ppNOC) or 6 h (NOP). PMA dose-dependently upregulated ppNOC
(pEC50: 0.45 (0.01–0.92)) and downregulated NOP mRNA (pIC50: 0.61 (0.30–0.92)). Medians and interquartile ranges, n¼4.
NOP: nociceptin opioid peptide receptor; ppNOC: prepronociceptin.
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for flow cytometry analysis are presented in Figure 4.
Nociceptin and NOP could both be detected at protein
levels in all blood leukocyte subsets by flow cytometry,
with higher medians of fluorescence intensity for nocicep-
tin and NOP compared to isotype controls (data not
shown). PMA significantly downregulated membrane
NOP expression in blood leukocyte subsets after 24 h com-
pared to controls (Figure 5). With regard to nociceptin, a
decrease in intracellular protein level was detected
in CD4þ T cells, CD8þ T cells, and NK cells in the
PMA-induced blood after 24 h, whereas no difference
was observed in granulocytes, monocytes, or B cells
(Figure 5).
Essential signaling pathways for the regulation of
ppNOC and NOP mRNA
To verify the contributions of ERK, JNK, p38, and
NFkB in the modulation of ppNOC and NOP mRNA
expression by PMA, specific kinase inhibitors (PD98509,
SP600125, SB203580, and Bay 11-7821) were employed.
PMA 10 ng/ml significantly increased ppNOC and
decreased NOP expression in blood leukocytes after 24
and 6 h, respectively, compared to control groups with-
out stimuli (both P <0.001). Pre-treatment of blood with
PD98509 or SB203580 partially prevented PMA effects
both on ppNOC as well as on NOP expression with a
1.9-fold (1.5-3.0) and a 2.6-fold (1.2-3.5) increase in
NOP mRNA compared to samples treated with PMA
only. In contrast, ppNOC mRNA levels decreased to
45.9% (31.6%–66.2%) and 41.1% (19.1%–51.7%) of
the PMA-treated samples (all P <0.05). The combina-
tion of PD98509 and SB203580 completely blocked
PMA-induced regulation of ppNOC (P=0.01) and
NOP (P <0.01). In addition, this combination produced
enhanced antagonistic effects compared to samples pre-
treated with kinase inhibitors PD98509 or SB203580. No
inhibiting effects of SP600125 and Bay 11-7821 were
Figure 2. Time courses of PMA-dependent effects on ppNOC and NOP mRNA expression. Whole blood was cultured with PMA or
without (control) for up to 72 h. Medians and interquartile ranges, n¼14 for each group. *P <0.05, **P <0.01, ***P <0.005.
NOP: nociceptin opioid peptide receptor; ppNOC: prepronociceptin; PMA: phorbol-12-myristate-13-acetate.
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observed on PMA-induced modulation of ppNOC and
NOP mRNA (Figure 6).
Discussion
This study focused on specific signal transduction path-
ways contributing to the modulation of nociceptin and
its receptor in human peripheral blood leukocytes.
Under inflammatory conditions, MAPK-ERK and p38
were the key signaling pathways regulating the nocicep-
tin system.
Nociceptin and its receptor are constitutively
expressed in human peripheral blood leukocytes at
Figure 4. Gating strategy used in flow cytometry analysis to detect different subsets in human peripheral blood leukocytes.
Figure 3. Nociceptin protein levels in blood culture supernatants. Whole blood was cultured with PMA or without (control) for 0, 24, or
48 h. Concentrations of nociceptin in supernatants at the start of the experiments were used to set a baseline. Box-and-whisker plots,
medians with interquartile ranges, and 5 to 95 percentiles, n¼13. ***P <0.005.
PMA: phorbol-12-myristate-13-acetate.
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mRNA as well as protein levels. Moreover, nociceptin
and NOP proteins were detected in all blood leukocyte
subsets and were regulated by PMA. These findings
underline the results of previous investigations demon-
strating that the nociceptin system directly participates
in immune response in peripheral blood under inflam-
matory conditions.3,14,15,24–26
Signaling pathways involved in ppNOC and NOP
mRNA expression
It has been well documented that human blood cells
respond to PMA exposure by activating a variety of
transduction pathways, including three MAPKs (ERK,
JNK, and p38) and the NFjB pathway.18,19 In the
present study, causal relationships between the ERK
and p38 signaling pathways and ppNOC and NOP
mRNA expression were shown by blocking respective
signaling cascades using specific kinase inhibitors.
Furthermore, the combination of PD98509 and
SB203580 led to synergistic inhibiting effects and
completely prevented PMA effects on ppNOC and
NOP expression. Taken together, PMA-activated ERK
and p38 MAPKs seem to represent key signaling path-
ways controlling the regulation of ppNOC and NOP
mRNA in human blood leukocytes. Deviation from
results obtained in previous investigations might be
due to species differences, tissue or cell specificity, and
varying inflammatory stimuli used. For instance, in a
human monocytic cell line (MM6 cultures), like ERK
Figure 5. Flow cytometric analysis of intracellular nociceptin and membrane NOP in blood leukocyte subsets. MFI represents the amount
of intracellular nociceptin or membrane NOP in blood leukocytes. Whole blood was cultured with or without PMA 10 ng/ml for 24 h.
Nociceptin and NOP protein levels in leukocyte subsets in blood samples without PMA co-incubation served as controls. Data are
presented as changes in nociceptin or NOP protein levels in subsets in the PMA group relative to the respective controls . Medians
and interquartile ranges, n=12 for each group. *P <0.05, **P <0.01, ***P <0.005, ****P <0.0001. PMA: phorbol-12-myristate-13-acetate;
NOP: nociceptin opioid peptide receptor.
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and p38, MAPK-JNK also contributed to the upregula-
tion of ppNOC mRNA by PMA.17 In contrast, in stud-
ies using in vitro culture models of rat astrocytes and
LPS or hydrogen peroxide as stimuli, the NFjB path-
way was involved in the induction of nociceptin tran-
scription in addition to MAPK-ERK and p38.16,27
Data concerning the regulation of the nociceptin recep-
tor have been scarce up to now. The present study con-
tributes to our knowledge of nociceptin receptor
regulation by revealing that ERK and p38 pathways
are also involved in its regulation in human
blood leukocytes.
Nociceptin and NOP protein profiles
Flow cytometry was employed to determine nociceptin
and NOP protein levels in blood leukocyte subsets. The
suppression of membrane NOP in all leukocyte subtypes
after culturing with PMA is in line with its mRNA pro-
file. For nociceptin, upregulation was most pronounced
at the mRNA level, whereas only a slight increase in
extracellular nociceptin was detected in the PMA
group after 24 h. However, decreased intracellular noci-
ceptin signals were observed in CD4þ T cells, CD8þ T
cells, and NK cells in PMA-treated blood. These
Figure 6. Influence of kinase inhibitors on ppNOC and NOP mRNA expression. ppNOC and NOP expression in blood leukocytes
cultured with PMA or without (control) and with or without pre-treatment with the specific kinase inhibitors PD98059 (PD, ERK
inhibitor) 30 lM, SB203580 (SB, p38 inhibitor) 10 lM, SP600125 (SP, JNK inhibitor) 10 lM, Bay 11-7821 (Bay, NFjB inhibitor) 3 lM, or the
combination of PD and SB. Box-and-whisker plots, medians with interquartile ranges, and 5 to 95 percentiles, n¼10 for the PDþSBþPMA
group, n¼17 for all other groups. *P <0.05, **P <0.01, ****P <0.0001.
NOP: nociceptin opioid peptide receptor; ppNOC: prepronociceptin; PMA: phorbol-12-myristate-13-acetate.
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findings, together with the FEIA results, indicate that
nociceptin is secreted by the blood leukocytes following
its synthesis under inflammatory conditions. In addition,
a short degradation half-life of nociceptin in mouse
plasma and brain was previously reported.28,29 Thus,
the extracellular secretion of nociceptin under inflamma-
tory conditions30,31 as well as the short half-life of this
peptide might be a possible explanation for the extracel-
lular and intracellular nociceptin protein profiles observed
in the present study. Alternatively, the detection of noci-
ceptin and NOP proteins in all blood leukocyte subsets
and their regulation upon PMA stimulation suggests that
the nociceptin system exerts considerable influence on
peripheral blood cells during inflammatory processes.
NOP-mediated activation of ERK, JNK, p38, and
NFjB signaling has been previously reported.32–38 In
the present study, nociceptin mRNA and nociceptin pro-
tein secreted into the supernatant increased in whole
blood cultures after PMA exposure. Therefore, it is pos-
sible that nociceptin synthesized and secreted by blood
leukocytes is involved in inflammation.
In contrast to LPS effects observed in a previous
study,13 PMA resulted in a significant upregulation of
ppNOC mRNA levels in our study. It has been well
documented that an LPS-mediated inflammatory
response in blood cells is quite different from PMA
effects, for example, different inflammatory cytokine
profiles are induced and different signal transduction
pathways are activated by these stimuli.39,40 In addition,
receptors for LPS are expressed on cell surfaces, while
phorbol ester receptors for PMA are predominantly
localized in the cytoplasm. Binding PMA to its receptor
activates protein kinase C and subsequently triggers
downstream signaling cascades. Therefore, inflammatory
substances participating in the regulation of the nocicep-
tin system and signal transduction pathways activated in
PMA- or LPS-induced blood cells may be different. Thus,
nociceptin and NOP expression profiles in blood leuko-
cytes under different inflammatory conditions, as well as
potential factors involved in their regulation, need to be
further investigated in future studies.
In the present study, antithetic regulation of nocicep-
tin and NOP by PMA was observed in different leuko-
cyte subsets. The differences indicate that the response of
subsets to PMA might vary. Exploration of the nocicep-
tin system specifically regulated in individual circulating
leukocyte subtypes may contribute to further under-
standing of their biologic function during pain process-
ing and inflammation. In addition, high biological
variability of nociceptin and NOP expression in periph-
eral blood samples was observed in the present setting.
Reasons for the high variability might include (1) the
fact that blood samples were obtained from different
volunteers, (2) the variations in response of blood
leukocytes to PMA treatment, and (3) genetic variation
in the expression of nociceptin and NOP.
Some limitations of the present investigation need to
be considered. Experiments were only performed in
PMA-induced whole blood. Although PMA-induced
whole blood is an optimal ex vivo culture model
mimicking pathological conditions,41 the cultures may
not accurately represent pathophysiological changes
occurring in vivo. Second, the involvement of signaling
pathways in the modulation of the nociceptin system was
investigated at mRNA levels only.
Whereas the function of the nociceptin system and
related mechanisms in the nervous system have been
well characterized, regulation of nociceptin and NOP
in human circulating blood has still not been fully eluci-
dated.23 Due to the widespread distribution of nocicep-
tin and NOP in the brain, spinal cord, and peripheral
organs and their role in physiological processes, NOP-
targeted compounds have entered clinical development
for various indications.3 The first published phase II ran-
domized controlled trial investigating patients suffering
from low back pain demonstrated the analgesic efficacy
of cebranopadol, a novel first-in-class analgesic drug
candidate combining agonistic activity at NOP and the
m-opioid receptor.4,5 This underlines the important step
from basic research to possible clinical use, as well as the
need for further investigations to clarify the role of
increased extracellular nociceptin in peripheral blood.
The contribution of signaling pathways to nociceptin
and NOP protein levels in different leukocyte subsets
needs to be addressed. Studies using whole blood cul-
tures and blood samples from patients with pain and/or
inflammatory diseases are necessary to fully elucidate
mechanisms contributing to the regulation of the noci-
ceptin system.
Conclusions
ERK and p38 are major signaling pathways contributing
to the PMA-induced regulation of nociceptin and the
nociceptin receptor in human whole blood cultures.
Elucidating mechanisms involved in the regulation of
nociceptin and its receptor may provide further insight
valuable for the development of drugs targeting the noci-
ceptin system.
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